

AMENDMENTS TO THE CLAIMS

Please cancel Claims 18, 44 and 54-56, without prejudice, as shown below in the following list of claims:

1. (Previously Presented) An ApoA-I agonist compound comprising:

(i) a 22 to 29-residue D-enantiomeric peptide or peptide analogue which forms an amphipathic α -helix in the presence of lipids and which comprises formula (I):

Z_1 -X₁-X₂-X₃-X₄-X₅-X₆-X₇-X₈-X₉-X₁₀-X₁₁-X₁₂-X₁₃-X₁₄-X₁₅-X₁₆-X₁₇-X₁₈-X₁₉-X₂₀-X₂₁-X₂₂-X₂₃-Z₂

or a pharmaceutically acceptable salt thereof, wherein:

X₁ is D-Ala (a), Gly (G), D-Gln (q), D-Asn (n), D-Asp (d) or D-Pro (p);

X₂ is a D-enantiomeric aliphatic residue;

X₃ is D-Leu (l) or D-Phe (f);

X₄ is a D-enantiomeric acidic residue;

X₅ is D-Leu (l) or D-Phe (f);

X₆ is D-Leu (l) or D-Phe (f);

X₇ is a D-enantiomeric hydrophilic residue;

X₈ is a D-enantiomeric acidic or a basic residue;

X₉ is D-Leu (l) or Gly (G);

X₁₀ is D-Leu (l), D-Trp (w) or Gly (G);

X₁₁ is a D-enantiomeric hydrophilic residue;

X₁₂ is a D-enantiomeric hydrophilic residue;

X₁₃ is Gly (G) or a D-enantiomeric aliphatic residue;

X₁₄ is D-Leu (l), D-Trp (w), Gly (G) or D-Nal;

X₁₅ is a D-enantiomeric hydrophilic residue;

X₁₆ is a D-enantiomeric hydrophobic residue;

X₁₇ is a D-enantiomeric hydrophobic residue;

X₁₈ is D-Gln (q), D-Asn (n) or a D-enantiomeric basic residue;

X₁₉ is D-Gln (q), D-Asn (n) or a D-enantiomeric basic residue;

X₂₀ is a D-enantiomeric basic residue;

X₂₁ is a D-enantiomeric aliphatic residue;

X₂₂ is a D-enantiomeric basic residue;

X₂₃ is absent or a D-enantiomeric basic residue;

Z₁ is R₂N- or RC(O)NR-;

Z₂ is -C(O)NRR, -C(O)OR or -C(O)OH or a salt thereof;

OK to
enter
2/16/06
PP